Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8⁺ T Cells

The tumor microenvironment is a complex network of different cell types comprising tumor, stromal, and immune cells, interspersed with blood and lymphatic vessels (1). The immune infiltrate in human tumors is heterogeneous depending on the tumor type and the individual. Several reports have identified tumor-infiltrating T cells directed against tumor-associated antigens, indicative of a spontaneous in situ immune response in patients with cancer (2–6). Moreover, a strong association between T-cell density with clinical outcome has been reported in many types of human solid cancer (7–13). More precisely, memory T cells with T-helper 1 (Th1) and cytotoxic orientations seem to represent a predominant T-cell population for prediction of favorable clinical outcome (14). In colorectal cancer, a comparison of the T-cell infiltrate with standard pathologic criteria demonstrated the prognostic power of immune criteria (7, 15, 16). These findings support the proposition that the T-cell infiltrate may serve as a new critical marker to aid in classifying cancers (17). Nevertheless, despite the well-recognized prognostic value of tumor-infiltrating lymphocytes (TIL) in some cancers, mechanisms that govern their recruitment and activation into the tumor remain unclear.

It is generally recognized that secondary lymphoid organs, comprising lymph nodes, spleen, and mucosal-associated lymphoid tissues are the primary site of induction of adaptive immune responses (18). In addition, organized lymphoid aggregates termed tertiary lymphoid structures (TLS) can develop locally, at sites of persistent inflammatory disorders. Lymphoid neogenesis has been described in various human pathologies, comprising infections, autoimmune diseases, and organ transplant rejections (19–21). TLS exhibit strong structural analogies with canonical secondary lymphoid organs and present features of an ongoing immune reaction site (22–24). Moreover, several studies in mouse models have demonstrated that TLS can induce a protective primary and secondary immune response independently of secondary lymphoid organs during respiratory viral infection (25, 26). However, the potential contribution of TLS to the promotion of an intratumoral immune reaction and their influence on the tumor immune contexture remain poorly investigated.

We have previously reported the presence of TLS in the tumor stroma of early-stage non–small cell lung cancer (NSCLC), composed of clusters of DC-Lamp⁺ mature dendritic cells (DC; referred as “TLS mature DC”) and T cells within T-cell area adjacent to B-cell follicle (27). These structures are surrounded by PNAd⁺ high endothelial venules (HEV), which are specialized blood vessels mediating lymphocyte extravasation into canonical lymphoid organs (28). Moreover, TLS were associated with a specific set of chemoattractant molecules involved in T-cell homing, suggesting their participation for the immigration of peripheral blood T cells into the tumor (29). In addition, DC-Lamp⁺ mature DC that home selectively in TLS have been associated with long-term survival in patients with early-stage NSCLC supporting the involvement of TLS in the promotion of a protective immunity (27). We hypothesized that TLS could represent a privileged site for the recruitment and activation of TIL in human lung tumors and aimed to evaluate the potential influence of these structures on the tumor immune contexture.

Here, we investigated the impact of the TLS on the immune contexture in 458 NSCLC comprising all stages of the disease. Using immunohistochemistry, flow cytometry, and quantitative real-time PCR, we demonstrated that TLS mature DC are strongly associated with a specific Th1 and cytotoxic immune signature and a long-term survival. In addition, the combination of mature DC and CD8⁺ T-cell densities constitutes a powerful and independent prognostic factor for overall survival (OS). Altogether, our data emphasize a major role for TLS in shaping the tumor immune contexture, and support their involvement in the promotion of a protective immune response mediated by T cells.

Fresh (n = 54 patients), frozen (n = 28 patients), and paraffin-embedded (n = 376 patients) primary lung tumor samples were obtained from patients with NSCLC who underwent a complete surgical resection of their lung tumors at Institut Mutualiste Montsouris or Hotel Dieu Hospital (Paris, France). Three hundred seventy-six patients with NSCLC operated between June 15, 2001, and November 26, 2004, were retrieved retrospectively. Patients who received neoadjuvant chemotherapy or radiotherapy were ineligible. The observation time of the cohort was the interval between the surgery and the last contact (last follow-up or death of the patient). At the completion of the study, the minimal clinical follow-up was 90 months for the last patient included in the cohort. The main clinical and pathologic features of the patients enrolled are presented in Table 1 for the retrospective study and in Supplementary Tables S1 and S2 for the prospective study on fresh and frozen tumors (20 common patients between the 2 prospective cohorts), respectively. The data on long-term outcomes were obtained retrospectively by interrogation of municipality registers or the family of patients. A written informed consent was obtained from the patients before inclusion in the prospective study. The protocol was approved by the local ethics committee (nos. 2008-133 and 2012-0612) in application with the article L.1121-1 of French law.

For each paraffin-embedded lung tumor, two observers (one expert pathologist and one investigator trained to identify the pathologic features of NSCLC) selected the tumor section containing a representative area of tumor with adjacent lung parenchyma, and the highest density of immune cells on the hematoxylin and eosin-safran–stained tissue section. Briefly, serial 5-μm tissue sections were deparaffinized, rehydrated, and pretreated in appropriate buffer for antigen retrieval. The sections were incubated with 5% human serum for 30 minutes before adding the appropriate primary antibodies followed by secondary antibodies (see Supplementary Table S3). Enzymatic activity was performed as described (27). For single staining, sections were counterstained with hematoxylin. Images were acquired using a Nanozoomer (Hamamatsu) operated with NDPview software.

The quantification of DC-Lamp⁺ DC was determined as previously described (27). CD8⁺ cells were enumerated in the tumor nests and the stroma of the whole tumor section with Calopix software (Tribvn), and expressed as an absolute number of positive cells/mm² of the areas of interest. Both immunostaining and quantification were reviewed by at least two independent observers (J. Goc, and R. Remark, T.K.D. Vo-Bourgais or M.-C. Dieu-Nosjean).

Fresh lung tumor specimens were mechanically (manual) dissociated and digested in the presence of Cell Recovery Solution (BD Biosciences) instead of enzymes that can remove CCR7 and CD62L at the cell surface. Then, total live mononuclear cells were isolated from the tumors, as previously described (29). Mononuclear cells were stained with multiple panels of antibodies conjugated to fluorescent dyes (see Supplementary Table S3). Briefly, after saturation with 2% human serum, mononuclear cells were incubated with the primary antibodies or appropriate isotype controls for 30 minutes at 4°C in the dark. Cells were washed and fixed in 0.5% formaldehyde before the analysis on a LSRII or Fortessa cytometer (BD Biosciences). Flow cytometry data were analyzed with the Diva (BD Biosciences) and FlowJo (TreeStar, Inc.) softwares. The gating strategies are explained in Supplementary Fig. S1.

Total RNA from frozen tissues was extracted with the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, and RNA quantity and quality were determined with 2100 Bioanalyzer (Agilent Technologies). Samples with a RNA integrity number ≥7 were reverse transcribed into cDNA using the High Capacity cDNA Kit (Life Technologies) according to the manufacturer's instructions.

Complementary DNA samples were amplified using the Low Density Array System according to the manufacturer's instructions (Applied Biosystems). The arrays (Human Immune Array; TaqMan) were processed on a TaqMan 2900HD (Life Technologies). Four nanograms of cDNA per qRT-PCR was used. Expression levels of genes were determined using threshold cycle (Ct) values normalized to β-actin expression as an endogenous control (ΔCt).

We used the Mann–Whitney test to compare the density of infiltrating immune cells in the different tumors. Correlations were performed using the Spearman test. OS curves were estimated by the Kaplan–Meier method and differences between the groups of patients were calculated using the log-rank test. The start of follow-up for OS was the time of surgery. Together with mature DC and CD8⁺ cell densities, the following available clinical parameters were tested: tumor–node–metastasis (TNM) stage according to the new classification 2009 (30), smoking history, histologic type according to the classification of the WHO (31), intervention type and emboli. With respect to immune cell densities, the “minimum P value” approach was used to determine the cutoff (Supplementary Fig. S2) for the best separation of patients referring to their OS outcome (outcome-oriented approach). Optimal cutoff values are 1.964, 383, and 114 cells per mm² for DC-Lamp⁺, CD8_S, and CD8_T cells, respectively. Because the P values obtained might be underestimated, OS log-rank P values were corrected using the formula proposed by Altman and colleagues (32) and validated using 100 repetitions of 2-fold cross-validations. We have also ensured that the significance established at the optimal cutoff remained valid at the quartiles (Supplementary Table S4). A P value of less than 0.05 was considered statistically significant. Parameters identified at univariate analysis as possibly influencing the outcome (P < 0.05) were introduced in a multivariate Cox-proportional hazards regression model. All analyses were performed with Prism 5 (GraphPad), Statview (Abacus Systems), and R (http://www.r-project.org/). Correlation matrix was represented with the Genesis software (Institute for Genomics and Bioinformatics, Gratz, Austria; ref. 33).

We performed large-scale flow cytometry analyses on 54 freshly resected human NSCLC to characterize the immune infiltrate according to the density of DC-Lamp⁺ mature DC (Fig. 1). We observed a significant higher percentage of total CD3⁺, CD3⁺CD4⁺, and CD3⁺CD8⁺ T cells, a nonsignificant trend for CD19⁺ B cells and no difference for CD3⁻CD56⁺ natural killer (NK) cells (Fig. 1A) among total live mononuclear cells from the tumor between patients with a high density of DC-Lamp⁺ DC (DC-Lamp^Hi patients) versus patients with a low density of DC-Lamp⁺ DC (DC-Lamp^Lo patients). DC-Lamp^Hi tumors had a significantly greater amount of CD62L⁺CD4⁺ and CD62L⁺CD8⁺ T cells than DC-Lamp^Lo tumors (Fig. 1B, left), in accordance with the selective localization of CD62L⁺ T cells inside the TLS (Supplementary Fig. S3; ref. 29). We also observed a significant and concomitant increase of antigen-experienced CD62L⁻CD4⁺ and CD62L⁻CD8⁺ T cells, which represent the majority of TIL among total mononuclear cells (Supplementary Fig. S4A), between DC-Lamp^Hi versus DC-Lamp^Lo tumors (Fig. 1B, right). Interestingly, a positive correlation was observed between the proportion of CD62L⁺ and CD62L⁻ T-cell subsets among total live mononuclear cells in the tumors (Supplementary Fig. S4B).

As compared with DC-Lamp^Lo tumors, DC-Lamp^Hi tumors were more infiltrated by activated CD38⁺ or CD69⁺ CD8⁺ T cells (Fig. 1C) and by the four main subpopulations of effector–memory CD8⁺ T cells (CD45RA⁻CCR7⁻CD27^{+ or −}CD28^{+ or −}; Fig. 1D) whereas no difference was seen for terminally differentiated effector–memory T cells (also called TEM-RA), which were detected at a very low frequency.

Altogether, these results demonstrate that DC-Lamp^Hi tumors have higher numbers of TLS T cells, as well as a higher number of activated and effector–memory non-TLS T cells, than DC-Lamp^Lo tumors.

Because the density of mature DC that home selectively in TLS is associated with an increased number of TIL, we next evaluated the impact of TLS on the functional characteristics of the immune cell infiltrate with a focus on T lymphocytes. Gene expression levels related to the main immune populations, TLS, Th1 and T-helper 2 (Th2) orientations, CD8⁺ T-cell cytotoxicity, T-cell activation, immunosuppression, inflammation, and angiogenesis were assessed in whole frozen tumors from 14 patients with DC-Lamp^Hi tumors, and compared with 14 patients with DC-Lamp^Lo tumors (Fig. 2A, Supplementary Fig. S5, and Supplementary Tables S2 and S5). As a control, genes related to the TLS cluster (CCL19, CCR7, CD28, CD62-L, and lymphotoxin-α) were significantly overexpressed among DC-Lamp^Hi versus DC-Lamp^Lo tumors (P = 0.0006). DC-Lamp^Hi tumors and not DC-Lamp^Lo tumors were also associated with the overexpression of sets of genes clustered into specific groups: immune cell populations (P = 0.0011), Th1 polarization (P = 0.0002), CD8⁺ T-cell cytotoxicity (P = 0.0013), and T-cell activation (P = 0.0005). Most of these molecules were detected at the protein level by immunohistochemistry and/or by flow cytometry on T cells: immune cells (Figs. 1 and 3; ref. 1), TLS signature (Fig. 1; ref. 29), Th1 orientation (Supplementary Fig. S6; ref. 27), chemokine receptors (29), and T-cell cytotoxicity and activation (Supplementary Fig. S6).

In contrast, genes involved in Th2 polarization, immunosuppression, inflammation (excepting CSF-2), and angiogenesis were not differentially expressed between the two groups of patients (Fig. 2A). We constructed a correlation matrix and demonstrated that the expression of all genes overexpressed among DC-Lamp^Hi tumors (immune cell subsets: CD3, CD4, CD8, CD20; TLS: CCL19, CCR7, CD28, CD62L, and LTA; Th1 orientation: CXCR3, IFN-γ, interleukin (IL)-2, IL-12B, IL-15, T-bet, and TNF-α; cytotoxicity: FAS-L, GNLY, GZMB, and PRF1; and T-cell activation: CCL5, CCR2, CCR4, CCR5, CD40L, CD86, CTLA-4, HLA-DRα, and ICOS) was also significantly correlated (correlation coefficient in Fig. 2B, and P value in Supplementary Fig. S7A and S7B).

Altogether, these results demonstrate that mature DC density correlates with a specific intratumoral immune contexture characterized by the overexpression and coordination of genes related to T-cell activation, Th1 orientation, and cytotoxic effector functions.

A correlation between CD8⁺ T-cell infiltration and a favorable clinical outcome was previously reported in many types of human solid cancer (8, 9, 13–15). As we observed a close association between mature DC density with cytotoxic effector function, we further investigated the relationship between mature DC and CD8⁺ T-cell infiltration. Because CD8⁺ T cells are expected to establish a contact with tumor cells to exert their cytolytic function, we discriminated CD8⁺ T cells present in the tumor nests and in the stroma in the following analysis.

In a retrospective series of 376 patients with NSCLC (Table 1), we quantified stromal CD8⁺ T cells (CD8_S), tumor nest CD8⁺ T cells (CD8_T), and mature DC-Lamp⁺ DC (Fig. 3A, B, and D). As previously observed in early-stage lung tumors (27), we confirmed that mature DC home selectively in the T-cell–rich areas of TLS (Fig. 3C and D) adjacent to PNAd⁺ vessels and B-cell follicles (Fig. 3E and F) in all stage lung tumors.

In accordance with the results above, we observed a higher density of both CD8_T and CD8_S cells (Fig. 3G) among DC-Lamp^Hi versus DC-Lamp^Lo tumors (mean = 254 vs. 138 CD8_T/mm², P = 0.0003; mean = 843 vs. 553 CD8_S/mm², P < 0.0001, respectively). Consequently, substratification of DC-Lamp^Hi and DC-Lamp^Lo patients according to CD8_S and CD8_T cell densities revealed that 84% of DC-Lamp^Hi patients were CD8^Hi in at least one region, and in particular 55% were high in both regions (Fig. 3H). These proportions were reduced in DC-Lamp^Lo patients with 61% of CD8^Hi in at least one region, and only 33% in both regions. Interestingly, patients with CD8_S^Lo/CD8_T^Hi tumors were rare in both DC-Lamp groups, in accordance with the trafficking of infiltrating T cells from the stroma to the tumor nests. The main differences between DC-Lamp^Hi versus DC-Lamp^Lo patients concerned the percentage of CD8_S^HiCD8_T^Hi and CD8_S^LoCD8_T^Lo patients whereas the percentages of mix groups (CD8_S^HiCD8_T^Lo and CD8_S^LoCD8_T^Hi) were quite unchanged. There were no distinguishable clinical characteristics [except for gender, histologic type, and pathologic TNM (pTNM) stage] between the patients with DC-Lamp^Hi versus DC-Lamp^Lo tumors (Supplementary Table S6). The gender and histologic type are also correlated, as most females were diagnosed with a squamous cell carcinoma (SCC; adenocarcinoma, SCC, and other types: 85%, 11%, and 4% of females, and 59%, 34%, and 7% of males, respectively, P = 0.0026). This observation may, in part, explain the differential distribution of gender and histologic type among the groups of DC-Lamp^Hi versus DC-Lamp^Lo patients. Using Cox multivariate regression analyses, we demonstrate that pTNM stage and DC-Lamp density were two independent prognostic factors (Supplementary Table S7).

Altogether, these results demonstrate that a high density of mature DC is closely related to a strong CD8⁺ T-cell infiltration.

Because we observed that high densities of CD8⁺ T cells were detected in both groups of DC-Lamp^Hi and DC-Lamp^Lo patients, we next evaluated the prognostic value of each variable alone and in combination (Fig. 4).

The Kaplan–Meier curves indicate that the densities of mature DC (P = 9.1 × 10⁻⁰⁵; Fig. 4A), CD8_S cells (P = 0.0019; Fig. 4B), and CD8_T cells (P = 0.0228; Fig. 4C) were correlated with longer OS.

Because the presence of mature DC and CD8⁺ cells in the tumors positively influence the outcome of patients with lung cancer, we stratified the patients into four groups according to the high or low density of each marker (DC-Lamp^Hi/CD8^Hi, DC-Lamp^Hi/CD8^Lo, DC-Lamp^Lo/CD8^Hi, and DC-Lamp^Lo/CD8^Lo; Fig. 4D). We observed that the group of patients with DC-Lamp^Hi tumors regardless of the density of CD8_S cells had the lowest risk of death (P = 3.4 × 10⁻⁰⁷, median OS were 92 months for DC-Lamp^Hi/CD8_S^Hi patients and 100 months for DC-Lamp^Hi/CD8_S^Lo patients), as was observed for DC-Lamp^Hi patients (Fig. 4A). Interestingly, only the DC-Lamp^Hi patients present an improved survival as compared with the whole cohort. In contrast, patients with a low density of both dendritic cells (DC) and CD8_S cells were at highest risk of death (median OS was 22 months) as compared with each immune marker alone (median OS: DC-Lamp^Lo = 36 months, CD8_S^Lo = 40 months). Patients with DC-Lamp^Lo/CD8_S^Hi tumors were at an intermediate risk of death (median OS = 41 months). Same results were obtained when the analysis was performed on the combination of DC-Lamp with CD8_T cells (data not shown). Additional analyses with 100 repetitions of 2-fold cross-validations confirmed the high and significant prognostic value of DC-Lamp/CD8_S score (cross-validated 99/100 tests, median P value = 4.7 × 10⁻⁰⁴). Using Cox multivariate regression analyses (Table 2), the pTNM stage and DC-Lamp/CD8_S score were the only criteria significantly and independently associated with OS (HR = 1.70 and 0.71, and P = 2.83 × 10⁻⁰⁷ and 4.50 × 10⁻⁰⁷, respectively).

All together, these data demonstrate that DC-Lamp alone is a good marker for the identification of patients with a favorable outcome whereas the combination of CD8 with DC-Lamp allows the identification of patients with the highest risk of death. Finally, the DC-Lamp/CD8_S score and pTNM stage constitute two independent and powerful prognostic factors.

The major clinical impact of TIL has emphasized the need to better identify the mechanisms underlying their recruitment and activation (14). Based on the structural analogy with lymph nodes, we hypothesized that lung tumor TLS could play a key role in the promotion of a local immune reaction. The ability of TLS to promote an efficient and protective T-cell response in many chronic inflammatory contexts (19–21) provided the rationale for this study.

By combining immunohistochemical and bio-molecular analyses, we demonstrated that a high density of TLS mature DC is associated with a specific immune orientation characterized by the overexpression and coordination of genes related to T-cell activation, Th1 polarization, and cytotoxic effector functions. By contrast, immune genes related to Th2 polarization, immunosuppression, inflammation, and angiogenesis were not differentially expressed between groups of patients with high or low densities of TLS mature DC. In agreement with these results, previous reports have also demonstrated that TLS correlated with an increased number of T-bet⁺ lymphocytes or high levels of cytotoxic gene expression in NSCLC and colorectal cancers, respectively (27,34). This specific Th1 and cytotoxic orientation related to mature DC density suggests a major influence of TLS mature DC in the shaping of the tumor immune contexture.

The significant increase of T-cell proportion, comprising CD62L⁺ T cells among the group of DC-Lamp^Hi versus DC-Lamp^Lo tumors, is in agreement with the selective presence of CD62L⁺ T cells located close to PNAd⁺ HEV (and vice versa) in TLS (29). Interestingly, a crucial role for DC in the maturation of HEV (35) and maintenance of TLS (22, 23) has been demonstrated in mice. In addition, close correlations between the density of HEV and lymphocyte infiltrate have been reported in melanoma (36, 37), human breast cancer (38), and in the methylcholanthrene-induced fibrosarcoma mouse model (39), which argue for functional features of HEV in tumor microenvironment. Altogether, these data strongly support that intratumoral HEV mediate recruitment of CD62L⁺ T cells from the blood into TLS, which could represent a major gateway for T cells into the tumor.

The density of TLS mature DC is also associated with a strong infiltration of experienced CD62L⁻ T cells that are predominantly of the effector–memory phenotype. These experienced T cells may derive, in part, from TLS CD62L⁺ T cells, which have undergone a local activation and differentiation. Studies in mouse models indicated that TLS could play a key role in the induction of a local immune response. Development of TLS was associated with the generation of specific CD8⁺ T cells and viral clearance in mice lacking secondary lymphoid organs (19, 20). A recent study also demonstrated that the activation, expansion, and differentiation of naïve CD8⁺ T cells into effector cells could occur directly in the tumors of mice with B16 melanoma and devoid of secondary lymphoid organs (40). These data highlight that extranodal activation of TIL is possible and can generate an immune response against the tumor independently of a response initiated in canonical lymphoid organs. Furthermore, de novo priming of tumor-infiltrating CD8⁺ naïve T cells has been described in TLS induced by modified vaccine virus Ankara demonstrating that these structures represent a major site for T-cell priming (23). Strikingly, induction of lymphoid neogenesis in tumors manipulated to express LIGHT (lymphotoxins, inducible expression, competes with HSV glycoprotein D for HVEM, expressed by T cells) or lymphotoxin-α generates a massive infiltration of naïve T cells, followed by T-cell activation, expansion, and tumors rejection (41, 42). Altogether, these data underline that TLS may serve as an important site for priming TIL during the generation of a local immune response.

Three major studies have previously reported strong associations between CD8⁺ T-cell infiltrate with the outcome of patients with lung cancer (9, 43, 44). In agreement with these data and similar results in many other types of cancers (8, 13–15), we found a strong correlation between CD8⁺ cell density and improved clinical outcome in patients with NSCLC. Compared with our first study performed in patients with early-stage NSCLC (27), we confirmed that mature DC density is still a favorable prognostic biomarker for patient survival (cohort of patients with stages I to IV NSCLC). Interestingly, patients with DC-Lamp^Hi/CD8^Lo tumors were scarce, arguing for a causal link between TLS and CD8⁺ cells density in which TLS would be an active site for CD8⁺ T-cell proliferation. More importantly among CD8^Hi patients, those with a concomitant DC-Lamp^Hi density had a significant clinical benefit as compared with patients with no or few TLS. Thus, DC-Lamp represents a new marker allowing the identification of CD8^Hi patients with elevated risk of death, and the combination of both variables allows the identification of a worst-risk group (DC-Lamp^Lo/CD8^Lo patients).

TLS could potentiate an antitumor CD8⁺ T-cell response in multiple ways. We previously reported that TLS T cells consisted primarily of CD4⁺ T cells (27, 29). Interestingly, a major role of CD4⁺ T-cell help for the recruitment, activation, and effector functions of naïve CD8⁺ T cells was demonstrated in a model of pancreatic tumors (45). This is consistent with the strong coordination between mature DC infiltration, Th1 polarization, T-cell activation, and cytotoxic orientation that we report in this study.

We speculate that TLS mature DC could present tumor-associated antigens that will promote continuous generation of specific T cells directly in the tumor. As a result, TLS could induce a local immune reaction that would be more adaptable to the shifting expression of tumor-associated antigens during tumor progression. A major challenge will now be to characterize and to compare the specificity of experienced T cells according to DC density to evaluate a potential association between TLS and clonal diversity of TIL.

Altogether, our results suggest that TLS represent a privileged area for T-cell recruitment and activation in the primary site of lung tumor, which could play a major role in the shaping of a tumor immune contexture with survival benefit. Lymphoid neogenesis could represent a major phenomenon to promote a protective immune response in lung or other types of cancer, which may provide new opportunities to improve immunotherapy strategies.

S.A. Hammond is an employee of MedImmune LLC/AstraZeneca and has ownership interest in AstraZeneca. No potential conflicts of interest were disclosed by the other authors.

Conception and design: J. Goc, L. de Chaisemartin, S.A. Hammond, C. Sautès-Fridman, M.-C. Dieu-Nosjean

Development of methodology: J. Goc, T.K.D. Vo-Bourgais, C. Klein, L. de Chaisemartin, D. Damotte, M.-C. Dieu-Nosjean

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Goc, T.K.D. Vo-Bourgais, A. Lupo, S. Knockaert, H. Ouakrim, M. Alifano, P. Validire, R. Remark, D. Damotte

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Goc, T.K.D. Vo-Bourgais, L. de Chaisemartin, E. Becht, S.A. Hammond, M.-C. Dieu-Nosjean

Writing, review, and/or revision of the manuscript: J. Goc, C. Germain, H. Ouakrim, S.A. Hammond, I. Cremer, W.-H. Fridman, C. Sautès-Fridman, M.-C. Dieu-Nosjean

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Goc, C. Germain, T.K.D. Vo-Bourgais, H. Ouakrim, P. Validire, D. Damotte, M.-C. Dieu-Nosjean

Study supervision: M.-C. Dieu-Nosjean

The authors thank Patricia Bonjour for technical assistance and Martine Bovet for help in clinical data collection. They also thank Estelle Devevre and Helene Fohrer-Ting from the “Centre d'Imagerie Cellulaire et de Cytométrie” (Cordeliers Research Center, Paris) for excellent technical assistance and support in flow cytometry.

This work was supported by the “Institut National de la Santé et de la Recherche Médicale,” the “Fondation ARC pour la recherche sur le cancer,” the “Cancéropôle Ile-de-France,” Université Paris-Descartes, Université Pierre et Marie Curie, Institut National du Cancer (2011-1-PLBIO-06-INSERM 6-1, PLBIO09-088-IDF-KROEMER), CARPEM (Cancer Research for Personalized Medicine), Labex Immuno-Oncology (LAXE62_9UMRS872 FRIDMAN), and MedImmune LLC.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.